Last abstract of #ACR23 was #ACRBest Plasma cfDNA signatures (synovial mapped) to identify RA vs OA, other inflamm arthritis Great performance, even with seroneg RA A blood test to: diagnose ?phenotype ?identify best b/tsDMARD Could be massive Peter Taylor ABST2586 @RheumNow https://t.co/tJX2jXV0Oe

#ACRbest Yrin Preview @ACRheum J Bathon Take home Symptomatic #Rx of ACPA+ people WITH #DMARD is too late to alter risk of #RA when drug is d/c AI to read joint erosions on X-ray May be ‘too little too late’ #Steroids in #RA increase #MACE even after d/c #ACR23 @RheumNow

#ACR23 Yr in Preview J Bathon Shared decision making w tradeoffs showed sex differences for concerns & preferences in #RA present dependent on how you ask the questions Unmet needs (I think 🤔) biomarkers of flare for #inflammatory #arthritis Rx select’n/retention @RheumNow

Watch: Assessment and Treatment of Cardiovascular Risks in Rheumatoid Arthritis Dr. Antoni Chan discusses abstract 0387 and abstract 0391 presented at #ACR23 https://t.co/avnarOGZui https://t.co/4CeAumv31b

• Assessment and Treatment of Cardiovascular Risks in Rheumatoid Arthritis | Rheu…

Telitacicept a recombinant fusion protein targeting, neutralizing BLyS and APRIL, phase 3 study in RA MTX-IR at 24 wk, ACR20 (60% vs 27% PBO), ACR50 (21% vs 6% PBO), reduced DAS28-ESR, no radiographic progression, Wang L Abst#L20 #ACR23 #ACRBest @RheumNow https://t.co/nuvizqQZsR https://t.co/PRtlea3AqU

Abstract 2583 at #ACR23 👉Possible predictive model of at risk of RA patients with ACPA positivity based on baseline levels of peripheral blood lymphocyte sub-populations: ⭐️High % of B cell and low % of NK cells increase the probability of developing arthritis in ACPA + pts… https://t.co/3KEOI4eul0 https://t.co/irX6InWMbl

A model for prediction of progression to RA Factors asso w/ progression -ACPAs -High % B cells -Low % NK cells Only in ACPA+ individuals Low ACPA titers, High % NK cells and Low B cells = 76% non progressors @RheumNow #ACR23 ABST2583 https://t.co/vNIwyrOJtJ

JAKi, especially BARI, may be useful and safe in controlling both pulmonary and joint disease in RA-ILD patients, even in refractory cases. Evolution of FVC and DLCO remained stable in first 12 months. Serrano-Combarro A, Abst#2174 #ACR23 @RheumNow https://t.co/82mMn5oh15 https://t.co/e7wrgmTOTA

Fecal microbiota - can it predict development of RA? Sadly, no. Despite promising mouse work. Despite relative control of exposure & genetic enrichment incl SE. Not even Prevotella. Maybe if you compare the most extreme cases but it’s not all the gut. #ACR23 ABST2584 @RheumNow https://t.co/VgDZaH9kvo

Pre-clinical RA trials roundup, but also: Great use (and acknowledgment) of RheumNow slide in the abstract background. Glad to see it being helpful there! #ACR23 ABST2585 @RheumNow https://t.co/sK6bDJrYjV

Treatment of RA-ILD patients with ABA at any time of the course in the ILD seems to prevent interstitial lung progression. The evolution of FVC and DLCO for 48 months remained stable with ABA therapy. Serrano-Combarro A, Abst#2173 #ACR23 @RheumNow https://t.co/QE61wzKWXi https://t.co/xd3wvMXUlA

L20 #ACR23 @RheumNow Telitacept - Recomb Fusion targets BlyS, APRIL in RA w inadeq MTX response ACR 20 60% v 27% PBO (p<0.001), ACR 50 21% v 6% PBO (p<0.001) DAS28-ESR <3.2 15% v 5%, reduct -1.6 v -1.0 Better PROs, less jt damage prog at w24 Safety SAE 6.4 v 6.7%, no ifn signal https://t.co/PsA6AxUHVW

#ACR23 Late-Breaking Abstr#L20 Phase 3 RCT in China: Telitacicept (BAFF-APRIL-i) in MTX-IR #RA met ACR20 response vs PBO. +ve: less radiographic damage -ve: lower rate ACR50 (21%), homogenous population, no H2H active comparator Unclear its place in current Mx @RheumNow https://t.co/SAc4B1aRD1

Telitacicept (BlyS/APRIL inhibitor) ph3 in RA wholly in China, after SLE approval there (SLE trial now w global sites) Efficacy okay, no better than other b/tsDMARDs What's the hook here, in a crowded RA market incl biosimilars? Safety does look good though #ACR23 L20 @RheumNow https://t.co/UzQ0f18E2A